Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA Vaccine in Chinese Adults 18-59 Years at Increased Risk of RSV
NCT07220109Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Oct 2025; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07220109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220109.